Abstract AB0552 – Table 1

n (%)	Primary aPL/APS n=38	SLE aPL/APS n=57	p
Mean Age (min-max)	41.7±10.5 (24-65)	42.9±10.0 (19-70)	0.57
Female	28 (74)	47 (83)	0.3
Thrombosis	18 (47)	24 (42)	0.61
Arterial	4 (10)	4 (7)	0.55
Venous	9 (24)	15 (26)	0.77
Arterial and venous	4 (10)	4 (7)	0.55
Transient Ischemic Attack	3 (8)	7 (12)	0.49
Pregnancy Morbidity*	10 (26)	11 (29)	0.42
Non-criteria aPL Manifestations	18 (47)	30 (53)	0.12
Livedo Reticularis	6 (16)	6 (11)	0.45
Thrombocytopenia	7 (18)	12 (21)	0.75
Hemolytic Anemia	0	11 (19)	0.004*
Valvular Heart Disease	8/32 (25)	13/55 (24)	0.43
Chronic Skin Ulcer	2 (5)	3 (5)	1.0
Biopsy proven aPL nephropathy	2 (5)	2 (4)	0.68
White Matter Changes	3/25 (12)	11/46 (24)	0.23
Positive Lupus Anticoagulant	22/35 (63)	33/57 (58)	0.79
Positive aCL (≥40 GPL/MPL)	25/37 (68)	44/57 (77)	0.30
IgG	15/25 (60)	35/44 (80)	0.08
IgM	11/25 (44)	20/44 (46)	0.77
Positive aβ ₂ GPI (≥40 GPL/MPL)	7/23 (18)	10/37 (18)	0.77
IgG	6/7 (86)	7/10 (70)	0.45
IgM	3/7 (49)	6/10 (60)	0.48
Medications at Database Entry			
Aspirin	19 (50)	37 (65)	0.15
Warfarin	20 (53)	29 (51)	0.87
Hydroxychloroquine	14 (37)	55 (97)	0.000*

*Defined based on the Updated Sapporo APS Classification Criteria

Conclusions: The analysis of our multicenter aPL database demonstrates that the frequencies of thrombosis and pregnancy morbidity are similar between aPL-positive patients with or without SLE. Half of the patients in both groups had history of at least one "non-criteria" aPL-manifestation; only autoimmune hemolytic anaemia was more frequent in aPL-positive patients with SLE.

REFERENCES:

- [1] Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. *Nat Rev Dis Primers* 2018;4:17103.
- [2] Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. *J Autoimmun* 2014;48–49:20–5.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6354

AB0553 CHARACTERISTICS OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG VARIOUS AGE GROUPS: COMPARISON BETWEEN JUVENILE ONSET, ADULT ONSET, AND LATE ONSET SYSTEMIC LUPUS PATIENTS FROM A SINGLE TERTIARY CENTRE IN EGYPT

B.M. Medhat, N. Sobhy, B. Eissa. *Rheumatology and Rehabilitation department, Faculty of Medicine-Cairo University, Cairo, Egypt*

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with several factors affecting the characteristics of the disease, including age of onset which is one of these major factors.¹

Objectives: To highlight the differences in disease characteristics among various age groups in an Egyptian cohort from a single tertiary centre.

Methods: Information in this study was derived from medical records of patients admitted to the Rheumatology department in Cairo University from December 2015 to June 2017. All patients fulfilled the SLICC classification criteria of 2012.² Demographic, clinical and serologic characteristics of all patients were recorded. Age of onset was defined as the age at the time of development of manifestations; upon which patients were divided into 3 groups: juvenile onset (JSLE: onset ≤16 years), adult onset (ASLE: onset 17–50), and late onset lupus (LSLE: onset >50) patients.

Results: The study included 369 patients, of which 44 (11.96%) were males and 324 (88.04%) were females. The mean age of onset of the cohort was 24.04 ±10.15 (7–63) years, while the mean disease duration was 65.6±58.4 (0.5–408) months. The study included 75/369 (20.3%) JSLE, 283/369 (76.6%) ASLE, and 10/369 (2.7%) LSLE patients. The median age of onset of JSLE patients was 13 (11–15), 23 (20–30) in ASLE patients, and 54 (52–58) years in the LSLE group. The median disease duration in JSLE patients was 78 (36–125), 36 (24–84) in ASLE patients, and 12 (9–38) months in LSLE patients. Apart from arthritis, malar

rash, and nephritis, there were no differences between the three groups. The prevalence of arthritis was highest among ASLE patients and lowest in JSLE (p=0.004) patients, with LSLE patients showing a comparable prevalence of arthritis to ASLE (p=0.5) and JSLE (p=0.3) patients. On the other hand, JSLE patients showed the highest prevalence of malar rash (p=0.006), as opposed to both ASLE (p=0.04) and LSLE (p=0.004) patients; yet ASLE patients showed a substantially high prevalence of malar rash when compared to LSLE patients (p=0.03). Nephritis was most common in JSLE patients (p=0.007) and least common in LSLE patients. Although there was no statistical difference in the prevalence of nephritis between JSLE and ASLE patients (p=0.1), both groups showed a higher prevalence of nephritis than LSLE patients (p=0.002 and p=0.01 respectively).

Conclusions: Adult onset SLE patients showed the highest prevalence of arthritis. On the other hand, JSLE patients showed the highest prevalence of nephritis as opposed to LSLE patients with the lowest prevalence, indicating a predilection towards a more severe disease in the former group.

REFERENCES:

- [1] Tucker LB, Uribe AG, Fernández M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). *Lupus* 2008; 17:314–322.
- [2] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis & Rheumatology* 2012;64:2677–86.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6565

AB0554 FACTORS AFFECTING QUALITY OF LIFE IN INDIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

B. Pinto¹, S. Grover², M. Rath³, A. Dhooia¹, A. Sharma¹. ¹Internal Medicine; ²Psychiatry; ³Nephrology, PGIMER, Chandigarh, India

Background: SLE has a profound impact on Quality of Life (QoL). In addition to disease activity and damage, other factors such as fatigue, fibromyalgia and psychiatric comorbidities also influence QoL.¹ However, there is lack of data in the form of comprehensive assessment of all these factors in the same cohort.

Objectives: To assess the quality of life and its correlates among patients with SLE.

Methods: Using a cross-sectional study design, 144 patients with SLE were assessed for disease activity and damage by using SELENA –SLEDAI and SLICC/ACR damage Index (SDI), depression (by using Patient Health Questionnaire-9 (PHQ9)), anxiety (by using Generalised Anxiety Disorder 7 (GAD7)), fatigue (by using Fatigue severity scale (FSS)) and fibromyalgia (as per using ACR 2010 criteria). QoL was assessed using a generic QoL scale – Short Form 36 (SF-36).² Statistical analysis was done using STATA version 14.

Results: The study sample included 140 females and 4 males. Mean age of the participants was 32.48 (SD-7.26) years and the mean duration of illness was 3.92 (SD-3.76) years. The mean SELENA SLEDAI and SDI was 3.42±4.04 and 0.26 ±0.65 respectively. Prevalence of depression (PHQ9 ≥10) and anxiety (GAD7 ≥10) was 25% and 22.9% respectively. Fatigue (FSS ≥4) was present in 51.4%. Physical domains of SF36 were affected more often than the mental domains, 71.5% of the respondents had scores less than 50 in Physical component Summary (PCS) and 61.1% in Mental Component Summary (MCS) of SF36. No correlation was found between disease activity and damage and various domains of SF36. Depression, anxiety and fatigue had a significant negative correlation with all the domains of SF36 (table 1). On multivariate regression only fatigue was an independent predictor of PCS of QoL.

Abstract AB0554 – Table 1. Spearman Correlation between various domains of SF36 and other variables

	SELENA SLEDAI	SDI	Fatigue (FSS)	Depression (PHQ9)	Anxiety (GAD7)
Physical Function	–0.1264	–0.0415	–0.3166**	–0.3307**	–0.2987**
Role Physical	–0.0996	–0.1082	–0.3004 **	–0.2304*	–0.2286*
Bodily pain	–0.0913	–0.1086	–0.3902**	–0.34**	–0.3549**
General health	–0.1681*	–0.1356	–0.3145**	–0.2486*	–0.3115**
Vitality	–0.1589	–0.0582	–0.4135**	–0.3595**	–0.3795**
Social function	–0.1645*	–0.096	–0.2619*	–0.3853**	–0.3732**
Role Emotional	0.0471	–0.0783	–0.1905*	–0.2389*	–0.2089*
Mental Health	–0.0025	–0.0123	–0.2811**	–0.4545**	–0.4873**
PCS	–0.2062*	–0.1136	–0.3875**	–0.2868**	–0.285**
MCS	–0.0139	–0.0265	–0.2673*	–0.4174**	–0.4253**

*p<0.05 **p<0.001